# BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

> **NCT01169675** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 53 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BIBW 2992 low dose
- **DRUG:** BIBW 2992 high dose
- **DRUG:** pemetrexed
- **DRUG:** pemetrexed
- **DRUG:** BIBW 2992 high dose 6 day
- **DRUG:** pemetrexed
- **DRUG:** pemetrexed
- **DRUG:** pemetrexed
- **DRUG:** pemetrexed
- **DRUG:** BIBW 2992 low dose 6 day
- **DRUG:** BIBW 2992 medium dose 6 day
- **DRUG:** BIBW 2992 medium dose

## Key facts

- **NCT ID:** NCT01169675
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01169675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01169675, "BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01169675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*